Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 3, 1998, Pages 143-154

  Walter, Mark R ^a,j   Bordens, Ronald ^b   Nagabhushan, Tattanahalli L ^b   Williams, Bryan R G ^c   Herberman, Ronald B ^d   Dinarello, Charles A ^e   Borden, Ernest C ^f   Trotta, Paul P ^g   Pestka, Sidney ^h   Pfeffer, Lawrence M ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Research Institute   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g Applied Clin Communications Inc   (United States)

^h RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^j Health Science Center ^*  (United States)

more..

Author keywords

Antiviral activity; Bioassay; Consensus interferon; Genes; Physicochemical properties; Receptor; Three dimensional structure

Indexed keywords

RECOMBINANT ALPHA2 INTERFERON;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; BIOASSAY; CANCER THERAPY; DRUG STRUCTURE; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 7344221471     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.143     Document Type: Review

References (56)

1. Issacs A and Lindenmann J. Virus interference I. The interferon. Proceedings of the Royal Society of Britain 1998;147:258.
2. Pestka S, Langer JA, Zoon KC, and Samuel CE. Interferons and their actions. Ann Rev Biochem 1987;56:727.
3. Nagabhushan TL and Trotta PP. Interferons, 5th Ullmann's Encyclopedia of Industrial Chemistry. VCH Verlagsgesellschaft: Weinheim, Germany. 1989;A14:365-380.
4. Trotta PP and Spiegel RJ. Interferon: Current concepts of mechanism of action. In: Concepts, clinical developments and therapeutic advances in cancer chemotherapy, MuggiaFM (ed.s), Martinus Nijhoff Publishers: Boston, MA. 1987;141-159.
5. Zoon KC, Bekisz J, and Miller D. Human interferon alpha family: protein structure and function. In: Interferons: Principles and medical applications, Baron S, Coppenhaver DH, Bianzani F, Fleischmann WRJ, Hughes TKJ, and Kumpel GR, et al (eds.), The University of Texas Medical Branch at Galveston, TX. 1992:95-105.
6. Alton KY, Stabinsky Y, Richards R, Ferguson B, Goldstein L, Altrock B, Miller L, and Stebbing N. Production, characterization and biological effects of recombinant DNA derived human IFN-alpha and IFN-gamma analogs. In: The biology of the interferon system, De Maeyer E and Schellekens H (eds.), Elsevier Science Publishers Amsterdam,Holland. 1983:119-128.
7. Rehberg E, Kelder B, Hoal EG, and Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. B Biol Chem 1982:257:11497.
8. Trotta PP, Le HV, Sharma B, and Nagabhushan TL. Isolation and purification of human alpha interferon, a recombinant DNA protein. In: Developments in industrial microbiology, Pierce G (ed.), Elsevier Science Publishers: Amsterdam, Holland. 1987:53-64.
9. Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, Pitha P, and Colamonici OR. Cloning and expression of a long form of the β subunit of the Interferon αβ receptor that is required for signaling. J Biol Chem 1995;270:21606
10. Novick D, Cohen B, and Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994;77:391.
11. Constantinescu SN, Croze E, Wang C, Murti A, Basu L, Mullersman JE, and Pfeffer LM Role of interferon α/β receptors chain 1 in the structure and transmembrane signaling of the interferon α/β receptor complex. Proc Natl Acad Sci USA 1994;91:9602.
12. Cohen B, Novick D, Barak S, and Rubinstein M. Ligand-induced association of the type I interferon receptor components. MoI Cell Biochem 1995;15:4208
13. Colamonici O, Yan H, Domanski P, Handa R, Smalley D, Mullersman J, Witte M, Krishnan K, and Krolewski J. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135 tyk2tyrosinekinase. Mol Cell Biochem 1994;14:8133.
14. Colamonici OR, Uyttendaele H, Domanski P, Yan H, and Krolewski JJ. P135, an interferon-α-activated tyrosine kinase, is physically associated with an interferon-a-receptor. J Biol Chem 1994;269:3518.
15. Yan H, Krishan K, Lim JTE, Contillo LG, and Krolewski JJ. Molecular characterization of an alpha interferon receptor 1 subunit (IFNαR1) domain required for TYK2 binding and signal transduction. Mol Cell Biol 1996:2074.
16. Miller DL, Kung HF, and Pestka S. Crystallization of recombinant human leukocyte interferon A. Science 1982;215:689.
17. 2b revealed by x-ray crystallography. Structure 1996,4:1453.
18. Streuli M, Nagata S, and Weissmann C. At least three human type α interferons: structure of α2. Science 1980;209:1343.
19. Goeddel DV, Leung DW, and Dull TJ. The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature 1981;290:20.
20. Diaz MO, Pomykala HM, Bohlander SK, Maltepe E, Malik K, Brownstein B, and Olopade OI. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 1994,22:540.
21. Pestka S. Invited paper. The human interferons - from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond. Arch Biochem Biophys 1983;221:1.
22. Pestka S. Interferon from 1981 to 1986 Methods in Enzymology. Academic Press. New York, NY. 1986;119:3-14.
23. Cantell K, Hirovonen S, Mogensen KE, and Pyhala L. Human leukocyte interferons: Production, purification, stability and animal experiments. The production and use of interferon for the treatment of human virus infections In: Vitro Monograph 3, Tissue Culture Association, Rockville, MD. 1984:35-38.
24. Familletti PC and Pestka S. Cell cultures producing human interferon. Antimicrob Agents Chemother 1981;20:1.
25. Familletti PC, McCandliss R, and Pestka S. Production of high levels of human leukocyte interferon from a continuous human myeloblast cell culture. Antimicrob Agents Chemother 1981;20:5.
26. Waldman AA, Miller RS, Familetti PC, Rubinstein S, and Pestka S. Induction and productin of interferon with human leukocytes from normal donors with the use of Newcastle disease virus. In. Methods in Enzymotogy, Pestka S (ed.), Academic Press: New York, NY 1981;78A:39-44.
27. Rubinstein M, Rubinstein S, Familetti PC, Miller RS, Waldman AA, and Pestka S. Human leukocyte interferon: production, purification to homogeneity, and initial characterization. Proc Natl Acad Sci USA 1979:640.
28. Evinger M, Rubinstein M, and Pestka S. Anti-proliferative and antiviral activities of human leukocyte interferons. Arch Biochem Biophys 1981;210:319.
29. Rubinstein M, Levy WP, Moschera JA, Lai C-Y, Hershberg RD, Bartlett RT, and Pestka S. Human leukocyte interferon: isolation and characterization of several molecular forms Arch Biochem Biophys 1981;210:307.
30. Bose S, Guari-Rotman D, Ruegg UT, and Anfinsen CB. Apparent dispensability of the carbohydrate moiety of human interferon for antiviral activity. J Biol Chem 1998;251:1659.
31. Bose S and Hickman J. Role of the carbohydrate moiety in determining the survival of interferon in the circulation. J Biol Chem 1977;252:8336.
32. Labdon JE, Gibson KD, Sun S, and Pestka S. Communication - some species of human leukocyte interferon are glycosylated. Arch Biochem Biophys 1984;232:422.
33. Adolf GR, Maurer-Fogy I, Kalsner I, and Cantell K. Purification and characterization of natural human interferon omega 1. Two alternative cleavage sites for the signal peptidase. Biochem J 1998;265:9290.
34. Adolf GR, Kalsner I, Ahom H, Maurer-Fogy I, and Cantell K. Natural human interferon-alpha2 is O-glycosylated. Biochem J 1991;276:511.
35. Maeda S, McCandliss R, Gross M, Sloma A, Familletti PC, Tabor JM, Evinger M, Levy WP, and Pestka S. Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. Proc Natl Acad Sci USA 1980;77:7010.
36. Nagata S, Taira H, Hall A, Johnsrud L, Strueli M, Ecsodi J, Boll W, Cantell, and Weissmann C. Synthesis in Escherichia-coli of a polypeptide with human-leukocyte interferon activity. Nature 1980;284:316.
37. Mogensen KE and Cantell K. Production and preparation of human leukocyte interferon. Pharmacol Ther 1977;1:369.
38. Mosmann TJ. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55.
39. DeLean A, Munson P, and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose response curves. Am J Physiol 1978;235:E97.
40. Harvey W, Srour EF, Turner R, Carey R, Maze R, Starrett R, Kanagala R, Pereira D, Merchant P, Taylor M, and Jansen J. Characterization of a new cell line (ESKOL) resembling hairy-cell leukemia a model for oncogene regulation and late B-cell differentiation. Leuk Res 1998;V15:P733.
41. Lydon NB, Favre C, Bove S, Neyret O, Benureau S, Levine AM, Seelig GF, Nagabhushan TL, and Trotta PP. Immunochemical mapping of α2 Interferon. Biochemistry 1985;24.4131.
42. Bazan JF. Structural design and molecular evoluation of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934.
43. Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, Zauodny PJ, and Narula SK. Crystal structure of a complex between interferon-gamma and its soluble high affinity receptor. Nature 1995;376:230.
44. Wells JA. Structural and functional basis for hormone finding and receptor oligomerization. Curr Biol 1994;6.163.
45. DeVos AM, Ultsch M, and Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992;255:306.
46. Mitsui Y, Senda T, Shimazu T, Matsuda S, and Utsumi J. Structural, functional and evolutionary implication of the three-dimensional crystal structure of murine interferon-β. Pharmacol Ther 1993;58:93.
47. Murgolo NJ, Windsor WT, Hruza A, Reichert P, Tsarbopoulos A, Baldwin S, Huang E, Pramanik B, Ealick S, and Trotta PP. A homology model of human interferon α2. Proteins-structure, function, and genetics 1993,17:62.
48. Uze G, Lutfalla G, and Mogensen KE. Alpha and Beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res 1995;15:3.
49. Gamble R, Petter NN, Trueman P, Newton CR, Carr FJ, Hockney RC, Moore VE, Greene AR, Holland D, and Edge MD. Functionally importnat conserved amino-acids in interferon-alpha-2 identified with analogues produced from synthetic genes. Biochem Biophys Res Commun 1986;134:1404.
50. Korn AP, Rose DR, and Fish EN. Three-dimensional model of a human interferon-alpha consensus sequence. J Interferon Res 1994;14:1.
51. Senda T, Saitoh S, and Mitsui Y. Refined crystal structure of recombinant murine interferon-β at 2.15 a resolution. J Mol Biol 1995;253:187.
52. Uze G, DiMarco S, Mouchel-Vielh E, Monneron D, Bandhu MT, Horisberger MA, Dorques A, Lutfalla G, and Mogensen KE. Domains of interaction between alpha interferon and its receptors components. J Mol Biol 1994;243:245.
53. Blatt LM, Davis JM, Klein SB, and Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996;16:489.
54. 2 biologically active on mouse cells. EMBO J 1987;6:591.
55. Nagabhushan TL and Giaquinto A. Interferon-α-2b: an overview from a regulatory perspective. In. Regulatory practice for biopharmaceutical production, Lubiniecki AS, Vargo SA (eds.), Wiley-Liss: New York. 1994:222-223.
56. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton J, and Hughes TK. The interferons Mechanisms of action and clinical applications. JAMA 1991;266:1375.